Form 8-K - Current report:
SEC Accession No. 0001628280-21-022599
Filing Date
2021-11-09
Accepted
2021-11-09 17:23:06
Documents
15
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20211109.htm   iXBRL 8-K 36033
2 EX-99.1 a2021q3-ex991er.htm EX-99.1 266588
7 cumberlandpharmaimageaa06a.jpg GRAPHIC 37721
  Complete submission text file 0001628280-21-022599.txt   540039

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20211109.xsd EX-101.SCH 2265
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20211109_def.xml EX-101.DEF 13058
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20211109_lab.xml EX-101.LAB 26049
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20211109_pre.xml EX-101.PRE 13936
8 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20211109_htm.xml XML 10591
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 211393355
SIC: 2834 Pharmaceutical Preparations